Advances in small molecule maintenance therapies for high-grade serous ovarian cancer

Fischetti, Margherita; Donato, Violante Di; Palaia, Innocenza; Perniola, Giorgia; Tomao, Federica; Perrone, Chiara; Giancotti, Antonella; Mascio, Daniele Di; Monti, Marco; Muzii, Ludovico; Panici, Pierluigi Benedetti; Bogani, Giorgio

doi:10.1080/14656566.2022.2154144

Cited by 6 publications

(19 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data suggest the utility of inhibiting both PARP-1 and PARP-2 to increase the efficacy of chemotherapy and to reduce tumor progression through an anti-angiogenic mechanism. 7,9,10 PARP intervenes in the repair of damage induced on DNA by therapeutic treatment of chemotherapeutic agents (alkylating agents and topoisomerase I inhibitors): PARP repairs alkylated bases. PARP activation is the basis for the phenomenon of tumor resistance to chemotherapy.…”

Section: Parp Inhibitors: Historymentioning

confidence: 99%

“…The "DSBs" of the damaged DNA remain unrepaired, resulting in growth arrest of cell growth, cell division, and even cancer cell death. 7,10 DNA repair mechanisms put into place by the neoplastic cells of the ovary, useful for their reproduction, can be inhibited by PARP inhibitors. 7,10 It all started in 1960, as we said before, with PARP 1 identification.…”

Section: Parp Inhibitors: Historymentioning

confidence: 99%

“…7,10 DNA repair mechanisms put into place by the neoplastic cells of the ovary, useful for their reproduction, can be inhibited by PARP inhibitors. 7,10 It all started in 1960, as we said before, with PARP 1 identification. In 1980 it was possible to clone PARP-1 and the clinical trials started.…”

Section: Parp Inhibitors: Historymentioning

confidence: 99%

“…Patients with BRCA mutation or with Homologous Recombination Deficiency (HRD) are going to experience excellent outcomes when treated with Poly (ADP-ribose) polymerase (PARP) inhibitors (PARP inhibitors). 7,8 Similarly, growing data highlighted that PARP-I might have a role even in patients without a deficit in their homologous recombination system. 7,8 In the present paper, we aim to discuss current evidence and further perspective on the role of PARP inhibitors in ovarian cancer patients.…”

mentioning

confidence: 99%

“…7,8 Similarly, growing data highlighted that PARP-I might have a role even in patients without a deficit in their homologous recombination system. 7,8 In the present paper, we aim to discuss current evidence and further perspective on the role of PARP inhibitors in ovarian cancer patients.…”

mentioning

confidence: 99%

See 4 more Smart Citations

PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer

Giannini

Dio

Donato

et al. 2023

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Ovarian cancer is the most lethal gynecologic malignancy, characterized by a high death-to-incidence ratio. Platinum-based chemotherapy is the mainstay of treatment for newly diagnosed and platinum-sensitive recurrent ovarian cancer. Poly (ADP-ribose) polymerase inhibitors (PARP inhibitors) have been incorporated into the treatment strategy for ovarian cancer. PARP inhibitors showed particular benefit for patients harboring defects in DNA repair pathways. Accumulating evidence showed that PARP inhibitors provide a benefit in newly diagnosed advanced ovarian cancer, even in the absence of BRCA mutation, as reported in the PRIMA, PRIME, and ATHENA-mono trials. Interestingly, the PAOLA-1 study provides another important finding, supporting the adoption of olaparib plus bevacizumab in patients with homologous recombination deficiency. Although those results are exciting, several patients develop resistance to PARP inhibitors. Hence, new combinations are under investigation to identify new treatment strategies to overcome this resistance. Currently, researchers are focused on the possibility to adopt PARP inhibitors even in the setting of platinum-resistant disease. The present critical review aims to report the current landscape and further perspective for strengthening PARP inhibitors' effectiveness in newly diagnosed and recurrent ovarian cancer.

show abstract

Section: Parp Inhibitors: Historymentioning

confidence: 99%